profit from every $100 of sales.
$0$100
Bio-Techne
$72.80-0.03% today
+23.0% in 1 year
1-year low $43.301-year high $72.83
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2021 to 2026.
0%20% a year
You pay $62.89 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bio-Techne sold, what it kept, and what it did with the cash.
Sales went from $1.14 billion in 2023 to $1.22 billion in 2026, with $182 million of profit last year.
SalesProfit
Bio-Techne handed back 35% of the cash it generated last year.
Buybacks $42M$50M
Free cash flow 2026$263M
Bought back its own shares$42M
Paid as dividends$50M
Cash vs. debt$265M vs. $289M
Bio-Techne vs. similar companies
Bio-Techne grows the slowest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bio-Techne | 62.9× · Very expensive | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Bio-Techne's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 931 | 1,106 | 1,137 | 1,159 | 1,220 | 1,215 | |
| 633 | 756 | 770 | 770 | 790 | 799 | |
| – | 296 | 291 | 246 | 243 | – | |
| 250 | 414 | 457 | 313 | 217 | 348 | |
| 140 | 272 | 285 | 168 | 73 | 182 | |
| 0.87 | 1.66 | 1.76 | 1.05 | 0.46 | 1.16 | |
| 68.0% | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% | |
| – | 26.8% | 25.6% | 21.3% | 19.9% | – | |
| 15.1% | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
Balance sheet
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Total assets | 2,263 | 2,295 | 2,639 | 2,704 | 2,558 | 2,587 |
| Cash | 199 | 173 | 181 | 152 | 162 | 265 |
| Total debt | 421 | 326 | 455 | 420 | 444 | 289 |
| Total liabilities | – | 594 | 672 | 635 | 639 | – |
| 1,563 | 1,702 | 1,967 | 2,069 | 1,919 | 2,108 | |
| 162 | 164 | 162 | 161 | 160 | 157 | |
| 6.5% | 12.2% | 11.4% | 6.4% | 3.6% | 8.2% | |
| 9.0% | 16.0% | 14.5% | 8.1% | 3.8% | 8.6% |
Cash flow
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 352 | 325 | 254 | 299 | 288 | 292 | |
| 44 | 45 | 38 | 63 | 31 | 29 | |
| 308 | 280 | 216 | 236 | 257 | 263 | |
| Dividends paid | 50 | 50 | 50 | 50 | 50 | 50 |
| 43 | 161 | 20 | 80 | 276 | 42 | |
| 49 | 42 | 39 | 38 | 41 | 41 |
Valuation
- 62.9×
- 36.7×
- 10.62
- 3.2×
- 9.4×
- 43.4×
- 33.0×
- 2.3%
- 1.6%
- 0.7%
Profitability
- 65.8%
- 19.9%
- 15.0%
- 21.4%
- 4.7%
- 8.4%
- 5.5%
- 4.3%
- 6.4%
- 8.0%
Growth
- +5.5%
- +5.9%
- +8.7%
- +0.0%
- +0.4%
Financial health
- 0.1×
- 0.14
- 11.4%
- 14.6×
- 4.49
- 3.18
- 0.47
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 47%of 958
Top 23%of 889
Bottom 17%of 601
Bottom 32%of 890
Top 41%of 987
What analysts expect
- Average price target
- $69.33
- Range
- $62.00 – $79.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.53 | 0.55 | −3.6% |
| Feb 4, 2026 | 0.46 | 0.43 | +7.0% |
| Nov 5, 2025 | 0.42 | 0.42 | −0.3% |
| Aug 6, 2025 | 0.53 | 0.50 | +6.1% |
| May 7, 2025 | 0.56 | 0.51 | +10.2% |
| Feb 5, 2025 | 0.42 | 0.39 | +8.8% |
| Oct 30, 2024 | 0.42 | 0.38 | +10.5% |
| Aug 7, 2024 | 0.49 | 0.49 | −1.0% |
0.7%of the share price, paid each year
On $1,000 invested$7a year at today's yield, before tax
+0.0%2020 to 2025
Raised–not every year
Paid per share, each year
$0.32 in 2015 → $0.32 in 2025
How safe it looks
27.5% of its profit
Room to growStretchedMore than it earns: 19.0%
News
Jensen Huang espionage controversy will cast a long shadow over Nvidia, veteran tech strategist warnsYahoo Finance · Nov 11, 2026Healthcare Just Hit a Record Lead Over Tech. 3 Things Could Shrink ItYahoo Finance · Nov 11, 2026What State Street Tech Select SPDR (XLK) Sold: Apple Leads on Nov. 9Yahoo Finance · Nov 11, 2026If the Tech Stock Sell-Off Turns Into a Bear Market, History Says This Investing Strategy Has Never FailedYahoo Finance · Nov 11, 2026Dan Ives Says Wall Street Is Underestimating 2 Major Tech StocksYahoo Finance · Nov 10, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
53No pass
Benjamin Graham
45No pass
Philip Fisher
48No pass
Peter Lynch
27No pass
Joel Greenblatt
2No pass
Charlie Munger
47No pass
Terry Smith
39No pass
Questions about Bio-Techne
Is Bio-Techne a good stock to buy?
A solid business, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bio-Techne AI analysis
What does Bio-Techne do?
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. It is in Biotechnology, based in Minneapolis, MN, United States, with 3,100 employees.
Does Bio-Techne pay a dividend?
Yes. At today's price the dividend is 0.7% a year, about 27% of its yearly profit. In 2026 it paid out $49.9 million in dividends.
Is Bio-Techne stock halal?
Yes. Bio-Techne passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Bio-Techne stock done over the past year?
Up 23.0% over the past twelve months, to $72.80. It traded between $43.30 and $72.83, close to its high.
Who are Bio-Techne's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Bio-Techne's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.